Pfizer, Moderna and AZ unveil trial protocols To view this email as a web page,
click here Roche's Actemra helps keep coronavirus patients off ventilators despite earlier trial flop Task force report urges Congress to support expanded telehealth. But here's why one doc group isn't happy with it Under pressure, Pfizer, Moderna (and soon AstraZeneca) publish COVID-19 vaccine protocols Sanofi, GlaxoSmithKline score EU supply pact for 300M coronavirus shots Biopharma roundup: Avigan generics nab COVID-19 green light in Russia; HHS Secretary Alex Azar drove push to strip FDA of lab test oversight: report Telehealth company Amwell spikes in public debut with outsized $742M IPO Time to take your shot, pharma: Pandemic offers best chance to reframe the conversation, brand expert says CareFirst, MedStar launch multiyear value-based care partnership Featured Story | By Angus Liu It looked like the end of road for the idea of targeting IL-6 to control serious pneumonia in COVID-19 patients when Sanofi and Regeneron’s Kevzara and Roche’s Actemra both flopped in clinical trials. But now, the Swiss pharma’s contender has staged a comeback—sort of. read more |
| |
|---|
|
Top Stories By Heather Landi Leading healthcare experts released a report this week outlining major policy recommendations to support the expanded use of telehealth in the wake of the COVID-19 pandemic. Here's why one physician group says the task force recommendations don't go far enough to support independent doctors. read more By Ben Adams The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder, especially after AstraZeneca’s trial was briefly stopped in the U.K. (and is still on hold in the U.S.). read more By Kyle Blankenship With the fourth quarter fast approaching, it's do-or-die time for a group of drugmakers' chasing the first approved vaccine for COVID-19. Sanofi and GlaxoSmithKline are running a bit behind other companies in terms of clinical testing, but that doesn't mean they aren't ready to sign their own momentous supply deals. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Russia approved two generic versions of Fujifilm's Avigan to treat COVID-19. HHS Secretary Alex Azar spearheaded last month's push to strip the FDA's oversight on lab-developed tests, Politico reported. Patchy data on antigen testing has obscured the true number of U.S. COVID-19 infections. And clinical trial suspensions are on the upswing once more, Phesi found. read more By Heather Landi Telehealth company Amwell saw its stock spike 42% in its first day of trading Thursday after raising an outsized initial public offering. The company's public debut may serve as a barometer for the telehealth market, which has seen business surge as the COVID-19 pandemic drives huge demand for remote care services. read more By Beth Snyder Bulik It's a once-in-a-generation opportunity for the pharma industry to rehabilitate its reputation as the COVID-19 pandemic swings consumer opinion. But while the door is open to long-term image repair, one expert warns pharma companies have to make real changes in the way they present themselves. read more By Paige Minemyer CareFirst BlueCross BlueShield and MedStar Health are teaming up to launch a value-based care initiative they say could save $400 million over the next seven years. read more |
|
